<DOC>
	<DOC>NCT01001091</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.</brief_summary>
	<brief_title>AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Presence of signs and symptoms of ocular inflammation in both eyes. Have a positive CAC response at Visit 1. Able to avoid the use of disallowed medications as well as contact lens wear for the specified period prior to Visit 1, and for the duration of the study. Other protocoldefined inclusion criteria may apply. Have known history or presence of persistent dry eye syndrome. Presence of any ophthalmic abnormality that may affect the study outcomes. Have a history of moderate to severe allergic asthma reaction to mountain cedar or the perennial allergens used in the study. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Conjunctivitis</keyword>
	<keyword>conjunctival inflammation</keyword>
	<keyword>ocular allergies</keyword>
</DOC>